ACI-35.030 (now called JNJ-2056), an active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the U.S. Food and Drug Administration (FDA). The drug candidate is being advanced into phase 2 trials, funded by Janssen Pharmaceuticals.
![[Health Valley] AC Immune receives FDA Fast Track Designation for Alzheimer’s Disease](https://republic-of-innovation.ch/wordpress/wp-content/uploads/2024/08/Ac-Immune.jpg)